A medicine spoils the moment it leaves its temperature
A vaccine that spends an hour above 8°C may be worthless, and nobody can see the damage. That is the problem the pharmaceutical cold chain exists to solve, and Singapore has built an unusually complete answer to it. The island manufactures a large volume of high-value medicine — biopharmaceutical facilities made S$12.1 billion of product in 2024, across more than 60 plants, with eight of the world’s ten largest drug companies operating here — and almost all of it leaves by a chain of refrigerated warehouses, reefer trucks and temperature-controlled aircraft holds that must never break. Changi Airport alone offers over 375,000 tonnes of annual cool-chain handling capacity. The cold chain is the quiet infrastructure that makes Singapore’s pharmaceutical trade possible.
Good Distribution Practice is the licence to touch a medicine
In Singapore the cold chain is not a service standard a company chooses; it is the law it operates under. The Health Sciences Authority (HSA) requires a Therapeutic Products Importer’s Licence to bring medicine in and a Therapeutic Products Wholesaler’s Licence to distribute it — and, critically, a company must comply with the Good Distribution Practice (GDP) standard before either licence is granted. GDP governs the whole handling chain: qualified storage, continuous temperature monitoring, validated transport, recall procedures and a named Responsible Person — typically a registered pharmacist — accountable for the quality system. A manufacturer holding a Therapeutic Products Manufacturer’s Licence is exempt for its own products, but everyone else who touches a medicine between factory and pharmacy sits inside this regime. GDP is why a Singapore distributor can prove, document by document, that a batch stayed in range from receipt to delivery.
Three temperature tiers, three different problems
The cold chain is not one temperature but a hierarchy, and each tier is harder than the last. The bulk of refrigerated medicine — most vaccines, insulin, many biologics — travels at 2-8°C, the standard “cold chain” band. Below that sits the frozen tier around -20°C for products that cannot survive refrigeration alone. The frontier is ultra-cold, roughly -60°C to -70°C, which the mRNA COVID-19 vaccines forced the industry to build at scale from 2020 — deep-freeze storage and dry-ice-packed transport that few operators could offer beforehand. Each step down multiplies the cost, the specialised equipment and the failure risk. A facility that can hold all three tiers under one GDP roof is rare, and it is the kind of capability Singapore’s larger operators have deliberately built.
Changi turned pharma handling into a shared standard
Airfreight is where a cold chain is most exposed — tarmac heat, transfers between warehouse and aircraft, waits on the apron — and Changi’s response was to make the whole community certify to one standard. In October 2017 the airport launched Pharma@Changi with nine founding partners, including SATS, dnata, DHL Global Forwarding, Schenker and Singapore Airlines Cargo, all holding IATA’s CEIV Pharma certification — the Center of Excellence for Independent Validators in Pharmaceutical Handling. It was the first such community in Asia-Pacific, and it matters because a pharma shipment is only as cold as its weakest handover: certifying the handler, the forwarder and the airline together closes the gaps between them. Changi now markets over 375,000 tonnes of annual cool-chain capacity on the back of it. One honest caveat: CEIV is an industry certification, not a government licence, and it does not by itself substitute for HSA’s GDP requirements — the two layers work together rather than one replacing the other.
Singapore distributes for the region, not just itself
The reason the cold chain is built to this depth is that Singapore is a regional distribution base, not merely a domestic market of six million. The clearest example is Zuellig Pharma, headquartered here since 1939 and one of Asia’s dominant healthcare distributors, operating across 16 markets, serving more than 200,000 medical facilities and working with over 450 clients including the world’s top 20 drug companies. In August 2023 it established a Singapore vaccine distribution hub with GSK covering 13 Asia-Pacific markets, running GDP cold-chain warehousing and shifting some routes to sea transport to cut emissions by at least 30% against airfreight, with blockchain traceability layered on top. A medicine made in a Tuas plant can be repackaged, held and dispatched from Singapore to a dozen countries — which is why the storage and the compliance are concentrated here.
The operators on the record
The cold chain is run by a small set of operators with the licences, the equipment and the certification to hold the line. Zuellig Pharma is the regional anchor — GDP-compliant refrigerated and frozen distribution for medicines and vaccines across Asia. SATS runs Coolport at the Changi Airfreight Centre, Singapore’s first dedicated on-airport perishables-and-pharma cold-chain centre, with temperature zones spanning ambient down to -28°C and CEIV Pharma certification. DHL operates a Life Sciences and Healthcare hub near Tuas Biomedical Park with GMP- and GDP-compliant ambient and 2-8°C cold rooms. Distinct from the pharma tier, Jurong Cold Store shows the frozen end at food scale — an automated high-bay holding 11,000 pallets at around -22°C — a reminder that the deep-freeze discipline the medicine trade depends on has a food-logistics twin. The wider field sits on the cold chain logistics capability page.